SOURCE: Dynavax Technologies

Dynavax Technologies

September 16, 2011 09:03 ET

Dynavax to Report Additional Immunogenicity Data for HEPLISAV™ Phase 3 Trial

BERKELEY, CA--(Marketwire - Sep 16, 2011) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that on Sunday, September 18, at 11:30 am CDT at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), the company will present additional immunogenicity data from its Phase 3 trial (HBV-16) evaluating the immunogenicity and safety of HEPLISAV versus Engerix-B®. Tyler Martin, M.D., President and Chief Medical Officer of Dynavax, will make an oral presentation in Session No. 80 "New Trends in Vaccines." The location of the presentation (#G1-534) is Meeting Room W194a of the McCormick Place convention center in Chicago, IL where the ICAAC annual meeting is taking place.


HEPLISAV is an investigational adult hepatitis B vaccine. In an earlier completed pivotal Phase 3 trial, HEPLISAV demonstrated increased, rapid protection with fewer doses than current licensed vaccines. Dynavax has worldwide commercial rights to HEPLISAV and is developing the vaccine for large, high-value populations that are less responsive to current licensed vaccines, including individuals with chronic kidney disease. HEPLISAV combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist known as ISS to enhance the immune response.

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Company's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide rapid and superior protection with fewer doses than current licensed vaccines. For more information visit

Engerix-B® is a registered trademark of GlaxoSmithKline

Contact Information

  • Contact:
    Michael Ostrach
    Vice President and Chief Business Officer
    Email Contact